Prof. Agnès Bernet to present at the 2025 Health Symposium in Paris

A novel therapeutic approach in endometriosis will be presented at the Health Symposium 2025, Université Paris-Cité.

Prof. Agnès Bernet will participate to the Health Symposium 2025, taking place November 24th – 25th at the Buffon Amphitheater at Université Paris-Cité (Paris 13th) and give the following talk :

« Netrin-1, a new therapeutic target in endometriosis »

Netrin-1 is a therapeutic target over-expressed in endometriotic lesions, paving the way to the potential development of the first true disease modifier in endometriosis. This chronic condition affects around one in ten women, is frequently associated with severe pelvic pain and fertility problems, and generates a major physical, emotional and socio-economic burden, that can profoundly impact women’s daily lives and long-term plans.

NP137, a monoclonal antibody developed by NETRIS Pharma targeting Netrin-1, is being developed to address both endometriosis-associated pain and lesion burden.

If you are attending the 2025 Health Symposium, we would be pleased to connect and exchange on this new approach to endometriosis and women’s health.